Key result
Gene therapy targeting the molecular basis of myocardial dysfunction, such as SERCA2a, has emerged as a viable adjunctive treatment option for advanced heart failure.
This review highlights the translational progress of gene therapy in heart failure, emphasizing improvements in vector delivery and the targeting of excitation-contraction coupling proteins.
Supports targeted gene therapy trials in advanced HF; extends molecular insights but leaves clinical efficacy unproven.
Advances in understanding the molecular basis of myocardial dysfunction, together with the evolution of increasingly efficient gene transfer technology, make gene-based therapy a promising treatment option for heart conditions. Cardiovascular gene therapy has benefitted from recent advancements in vector technology, design, and delivery modalities. There is a critical need to explore new therapeutic approaches in heart failure, and gene therapy has emerged as a viable alternative. Advances in understanding of the molecular basis of myocardial dysfunction, together with the development of increasingly efficient gene transfer technology, has placed heart failure within reach of gene-based therapy. The recent successful and safe completion of a phase 2 trial targeting the cardiac sarcoplasmic/endoplasmic reticulum Ca2+ ATPase pump (SERCA2a) has the potential to open a new era for gene therapy for heart failure.
No takes yet. Share an insight, caveat, or question.
Roger J. Hajjar (2013) conducted a review in Heart failure. Gene therapy was evaluated. Gene therapy targeting the molecular basis of myocardial dysfunction, such as SERCA2a, has emerged as a viable adjunctive treatment option for advanced heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: